Home Stock

Stock Research: Knight Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Knight Therapeutics

TOR:GUD CA4990531069
75
  • Value
    48
  • Growth
    80
  • Safety
    Safety
    94
  • Combined
    89
  • Sentiment
    23
  • 360° View
    360° View
    75
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Knight Therapeutics Inc. is a specialty pharmaceutical company. It operates in the pharmaceutical industry, developing, acquiring, and distributing pharmaceutical products. The company operates in Canada, Latin America, and select international markets. In the last fiscal year, the company had a market cap of $442 million, profits of $121 million, and revenue of $258 million, with 745 employees.

more

ANALYSIS: With an Obermatt 360° View of 75 (better than 75% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Knight Therapeutics are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Knight Therapeutics. The consolidated Growth Rank has a good rank of 80, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 80% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 94 which means that the company has a financing structure that is safer than 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 48 which means that the share price of Knight Therapeutics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 52% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 23, which means that professional investors are more pessimistic about the stock than for 77% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Refinancing
Country Canada
Industry Pharmaceuticals
Size Small
Website knighttx.com
Index
Knight Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 41 39 45
Growth
80 29 41 15
Safety
Safety
94 89 91 68
Sentiment
23 86 87 50
360° View
360° View
75 74 80 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
20 75 49 69
Opinions Change
50 50 50 50
Pro Holdings
n/a 55 73 16
Market Pulse
55 85 93 64
Sentiment
23 86 87 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 41 39 45
Growth
80 29 41 15
Safety Safety
94 89 91 68
Combined
89 55 64 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
86 59 60 64
Price vs. Earnings (P/E)
5 7 5 4
Price vs. Book (P/B)
73 80 79 85
Dividend Yield
1 1 1 1
Value
48 41 39 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
70 15 18 45
Profit Growth
73 80 93 25
Capital Growth
81 24 29 1
Stock Returns
34 51 57 71
Growth
80 29 41 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
50 75 78 79
Refinancing
96 82 77 55
Liquidity
62 41 43 25
Safety Safety
94 89 91 68

Similar Stocks

Discover high‑ranked alternatives to Knight Therapeutics and broaden your portfolio horizons.

Teck

TOR:TECK.B
Country: Canada
Industry: Diversified Metals & Mining
Size: X-Large
Full Stock Analysis

Agilent

NYQ:A
Country: USA
Industry: Life Sciences Tools & Services
Size: X-Large
Full Stock Analysis

Fairfax India Holdings

TOR:FIH.U
Country: Canada
Industry: Asset Management & Custody
Size: Medium
Full Stock Analysis

Suncor

TOR:SU
Country: Canada
Industry: Oil & Gas Integrated
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews